Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis

Objective Tolvaptan was first approved for use for cirrhosis in Japan in September 2013. The aim of the study was to examine the effect of tolvaptan, a vasopressin V2 receptor antagonist, on the prognosis of cirrhosis. Methods The effect of tolvaptan was evaluated in 26 patients with cirrhosis treat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Intern Med
Autori principali: Iwamoto, Takuya, Maeda, Masaki, Hisanaga, Takuro, Saeki, Issei, Fujisawa, Koichi, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Natura: Artigo
Lingua:Inglês
Pubblicazione: The Japanese Society of Internal Medicine 2016
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5109555/
https://ncbi.nlm.nih.gov/pubmed/27746425
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi